Last reviewed · How we verify

lorundrostat Dose 1 — Competitive Intelligence Brief

lorundrostat Dose 1 (lorundrostat Dose 1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 11β-HSD1 inhibitor. Area: Metabolic disorders.

phase 3 11β-HSD1 inhibitor 11β-HSD1 Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

lorundrostat Dose 1 (lorundrostat Dose 1) — Mineralys Therapeutics Inc.. Lorundrostat is a selective, reversible inhibitor of 11β-HSD1.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
lorundrostat Dose 1 TARGET lorundrostat Dose 1 Mineralys Therapeutics Inc. phase 3 11β-HSD1 inhibitor 11β-HSD1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (11β-HSD1 inhibitor class)

  1. Creabilis SA · 2 drugs in this class
  2. Mineralys Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lorundrostat Dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/lorundrostat-dose-1. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: